Edition:
United States

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.21EUR
5:45am EDT
Change (% chg)

€0.00 (+0.33%)
Prev Close
€1.21
Open
€1.21
Day's High
€1.22
Day's Low
€1.21
Volume
18,343
Avg. Vol
140,773
52-wk High
€4.68
52-wk Low
€0.98

Chart for

About

Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet... (more)

Overall

Beta: 0.85
Market Cap(Mil.): €61.19
Shares Outstanding(Mil.): 50.70
Dividend: --
Yield (%): --

Financials

  C4X.PA Industry Sector
P/E (TTM): -- 29.56 34.14
EPS (TTM): -1.16 -- --
ROI: -68.72 13.56 13.10
ROE: -82.06 15.35 15.09

BRIEF-Onxeo Announces Start Of DRIIV Phase 1 Clinical Study Of AsiDNA

* ANNOUNCES START OF DRIIV, PHASE 1 CLINICAL STUDY OF ASIDNA IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 24 2018

BRIEF-Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million

* FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO

Mar 29 2018

BRIEF-Onxeo Presents Positive AsiDNA Preclinical Study Results

* ANNOUNCES PRESENTATION OF TWO PRECLINICAL STUDY ABSTRACTS HIGHLIGHTING ASIDNA

Mar 15 2018

BRIEF-Onxeo Says To Record Impairment Charge

* ONXEO SA SAYS IT WILL RECORD AN IMPAIRMENT CHARGE OF ABOUT EUR 38 MILLION IN ITS 2017 CONSOLIDATED ACCOUNTS

Mar 14 2018

BRIEF-Onxeo Provides Update on Litigation with SpeBio/SpePharm

* ONXEO SA - SUBMITTED CONCLUSIONS TO PARIS COURT OF APPEAL CONCERNING MERITS OF LITIGATION AGAINST SPEPHARM/SPEBIO B.V COMPANIES

Jan 23 2018

Earnings vs. Estimates